Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis

Abstract

Objective: With a steadily rising prevalence, nonalcoholic fatty liver disease (NAFLD) was a leading global cause of liver-related health problems. In the clinical management of NAFLD, various western pharmaceuticals were widely utilized. This network meta-analysis aimed to evaluate the effectiveness of common western medications for NAFLD patients.

Methods: We systematically reviewed and screened articles based on predesigned criterion about western medications for NAFLD, which were from Embase, Cochrane Library, PubMed, CNKI, WanFang, and China Science and Technology Journal Database until August 1, 2024. Eligible studies included randomized controlled trials of patients aged 18 or older with NAFLD, comparing Western medicines to placebos or other Western medicine treatments. The risk of bias assessment tool 2.0 from the Cochrane system was used to assess the quality of the included articles. A Bayesian network meta-analysis was conducted using WinBUGS 1.4.3 with a random-effectsmodel and Markov Chain Monte Carlo methods. Treatment rankingswere based on Surface Under the Cumulative Ranking Curve (SUCRA) values, and heterogeneity was assessed with I² and Q statistics. The outcomes were analyzed in WinBUGS and visualized using Stata 14.0, generating network plots and cumulative probability rankings to compare treatment effects. The systematic review was registered in PROSPERO (CRD42024509176).

Results: Based on 37 included articles involving 7673 patients, pioglitazone demonstrated the most significant effects in resolving nonalcoholic steatohepatitis without worsening fibrosis, increasing high-density lipoprotein cholesterol levels, and achieving a ≥ 2-point reduction in NAFLD activity scores (odds ratio [OR] = 0.09, 95% confidence interval [CI]: 0.01 to 0.81), with a SUCRA probability of 91.4%. Aldafermin showed remarkable effects in improving liver function markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase, with cumulative probabilities of 90% for ALT and 69.8% for AST. Cluster analysis revealed that Resmetirom and Aldafermin were superior options for enhancing liver function, while pioglitazone emerged as the best treatment for the comprehensive improvement of NAFLD.

Conclusions: Pioglitazone outperformed other western medicines in terms of overall efficacy when treating NAFLD, but Aldafermin and Resmetirom showed superior improvement in liver function. This study provided a certain level of support for the use of specific clinical medications.

Keywords

clinical assessment / network meta-analysis / nonalcoholic fatty liver disease / pioglitazone / treatment efficacy

References

[1] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association,“Guidelines for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (2018 Update), ” Journal of Clinical Hepatology 34, no. 05 2018:947–957.

[2] X. Guo,X. Yin,Z. Liu, and J. Wang,“Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment, ” International Journal of Molecular Sciences 23, no. 24 (2022).

[3] M. V. Machado and A. M. Diehl,“Pathogenesis of Nonalcoholic Steatohepatitis, ” Gastroenterology 150, no. 8 (2016):1769–1777.

[4] E. E. Powell,V. W. Wong, and M. Rinella,“Non-Alcoholic Fatty Liver Disease, ” Lancet 397, no. 10290 (2021):2212–2224.

[5] C. Estes,Q. M. Anstee,M. T Arias-Loste, et al.,“United Kingdom, and United States for the Period 2016–2030, ” Journal of Hepatology 69, no. 4 (2018):896–904. Modeling NAFLD disease burden in China.

[6] M. S. Mundi,S. Velapati,J. Patel,T. A. Kellogg,B. K. A. Dayyeh, and R. T. Hurt,“Evolution of NAFLD and Its Management, ” Nutrition in Clinical Practice 35, no. 1 (2020):72–84.

[7] Z. R. Zhang,C. H. Yu,Y. An,X. He,Y. Guo,J. Y. Deng, et al.,“Comparative Study on the Quality Assessment and Recommendations of Clinical Guidelines and Consensus for Non-Alcoholic Fatty Liver Disease, ” Chinese Journal of General Practice 26, no. 20 (2023):2439–2446.

[8] B. Hutton,G. Salanti,D. M. Caldwell, et al.,“The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations, ” Annals of Internal Medicine 162, no. 11 (2015):777–784.

[9] D. E. Kleiner,E. M. Brunt,M. Van Natta, et al.,“Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease, ” Hepatology 41, no. 6 (2005):1313–1321.

[10] Z. M. Younossi,M. Stepanova,N. Rafiq, et al.,“Pathologic Criteria for Nonalcoholic Steatohepatitis: Interprotocol Agreement and Ability to Predict Liver-related Mortality, ” Hepatology 53, no. 6 (2011):1874–1882.

[11] M. Ekstedt,H. Hagström,P. Nasr, et al.,“Fibrosis Stage Is the Strongest Predictor for Disease-specific Mortality in NAFLD After up to 33 Years of Follow-Up, ” Hepatology 61, no. 5 (2015):1547–1554.

[12] J. P. Higgins,D. G. Altman,P. C. Gøtzsche, et al.,“The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials, ” BMJ (Clinical Research Ed) 343 (2011): d5928.

[13] S. A. Harrison,R. Taub,G. W. Neff, et al.,“Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial, ” Nature Medicine 29, no. 11 (2023):2919–2928.

[14] R. Loomba,M. F. Abdelmalek,M. J. Armstrong, et al.,“Semaglutide 2·4 mg Once Weekly in Patients With Non-Alcoholic Steatohepatitis-Related Cirrhosis: A Randomised, Placebo-Controlled Phase 2 Trial, ” The Lancet Gastroenterology and Hepatology 8, no. 6 (2023):511–522.

[15] V. Šmíd,K. Dvořák,P. Šedivý, et al.,“Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients with Metabolic Syndrome and NAFLD, ” Hepatology Communications 6, no. 6 (2022):1336–1349.

[16] H. Chehrehgosha,M. R. Sohrabi,F. Ismail-Beigi, et al.,“Empagliflozin Improves Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, ” Diabetes Therapy 12, no. 3 (2021):843–861.

[17] S. A. Harrison,G. Neff,C. D. Guy, et al.,“Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis, ” Gastroenterology 160, no. 1 (2021):219–231.

[18] M. H. Mohamad Nor,N. Ayob,N. M. Mokhtar, et al.,“The Effect of Probiotics (MCP(®) BCMC(®) Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients With Non-Alcoholic Fatty Liver Disease, ” Nutrients 13, no. 9 (2021).

[19] A. Fouda,A. E. Abdelaziz,M. Hussien,A. A. Ali,K. S. Abdelkawy, and F. Elbarbry,“A Randomized Controlled Trial Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxifylline on Egyptian Non-Alcoholic Steatohepatitis Patients, ” European Review for Medical and Pharmacological Sciences 25, no. 23 (2021):7449–7459.

[20] J. F. Huang,C. Y. Dai,C. F. Huang, et al.,“First-in-Asian Double-blind Randomized Trial to Assess the Efficacy and Safety of Insulin Sensitizer in Nonalcoholic Steatohepatitis Patients, ” Hepatology International 15, no. 5 (2021):1136–1147.

[21] P. N. Newsome,M. Palmer,B. Freilich, et al.,“Volixibat in Adults With Non-Alcoholic Steatohepatitis:24-week Interim Analysis From a Randomized, Phase II Study, ” Journal of Hepatology 73, no. 2 (2020):231–240.

[22] S. A. Harrison,Z. Goodman,A. Jabbar, et al.,“A Randomized, Placebo-Controlled Trial of Emricasan in Patients With NASH and F1-F3 Fibrosis, ” Journal of Hepatology 72, no. 5 (2020):816–827.

[23] S. A. Harrison,N. Alkhouri,B. A. Davison, et al.,“Insulin Sensitizer MSDC-0602K in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study, ” Journal of Hepatology 72, no. 4 (2020):613–626.

[24] S. A. Harrison,V. W. Wong,T. Okanoue, et al.,“Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results From Randomized Phase III STELLAR Trials, ” Journal of Hepatology 73, no. 1 (2020):26–39.

[25] H. Taheri,M. Malek,F. Ismail-Beigi, et al.,“Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial, ” Advances in Therapy 37, no. 11 (2020):4697–4708.

[26] C. K. Kedarisetty,A. Bhardwaj,G. Kumar, et al.,“Efficacy of Combining Pentoxiphylline and Vitamin E Versus Vitamin E Alone in Non-Alcoholic Steatohepatitis—A Randomized Pilot Study, ” Indian Journal of Gastroenterology 40, no. 1 (2021):41–49.

[27] M. A. Pervez,D. A. Khan,A. U. R. Slehria, and A. Ijaz,“Delta-Tocotrienol Supplementation Improves Biochemical Markers of Hepatocellular Injury and Steatosis in Patients With Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled Trial, ” Complementary Therapies in Medicine 52 (2020):102494.

[28] F. Bril,D. M. Biernacki,S. Kalavalapalli, et al.,“Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial, ” Diabetes Care 42, no. 8 (2019):1481–1488.

[29] S. A. Harrison,M. R. Bashir,C. D. Guy, et al.,“Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial, ” Lancet 394, no. 10213 (2019):2012–2024.

[30] Z. M. Younossi,V. Ratziu,R. Loomba, et al.,“Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial, ” Lancet 394, no. 10215 (2019):2184–2196.

[31] V. J. Navarro,S. H. Belle,M. D’Amato,N. Adfhal,E. M. Brunt,M. W. Fried, et al.,“Silymarin in Non-Cirrhotics With Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo Controlled Trial, ” PLoS ONE 14, no. 9 (2019): e0221683.

[32] A. Anushiravani,N. Haddadi,M. Pourfarmanbar, and V. Mohammadkarimi,“Treatment Options for Nonalcoholic Fatty Liver Disease: A Double-Blinded Randomized Placebo-Controlled Trial, ” European Journal of Gastroenterology &Hepatology 31, no. 5 (2019):613–617.

[33] S. B. Ahn,D. W. Jun,B. K. Kang,J. H. Lim,S. Lim, and C. M. J. Randomized,“Double-Blind, Placebo-Controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease, ” Scientific Reports 9, no. 1 (2019):5688.

[34] J. Oscarsson,K. Önnerhag,U. Risérus, et al.,“Effects of Free Omega-3 Carboxylic Acids and Fenofibrate on Liver Fat Content in Patients With Hypertriglyceridemia and Non-Alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Study, ” J Clin Lipidol 12, no. 6 (2018):1390–1403.

[35] S. McPherson,N. Wilkinson,D. Tiniakos, et al.,“A Randomised Controlled Trial of Losartan as an Anti-Fibrotic Agent in Non-Alcoholic Steatohepatitis, ” PLoS ONE 12, no. 4 (2017): e0175717.

[36] T. R. Joy,C. A. McKenzie,R. G. Tirona, et al.,“Sitagliptin in Patients With Non-Alcoholic Steatohepatitis: A Randomized, Placebo-Controlled Trial, ” World Journal of Gastroenterology 23, no. 1 (2017):141–150.

[37] V. Ratziu,S. A. Harrison,S. Francque, et al.,“Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening, ” Gastroenterology 150, no. 5 (2016):1147–1159.

[38] K. Cusi,B. Orsak,F. Bril, et al.,“Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial, ” Annals of Internal Medicine 165, no. 5 (2016):305–315.

[39] M. Bahrami,M. Cheraghpour,S. Jafarirad, et al.,“The Effect of Melatonin on Treatment of Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Double Blind Clinical Trial, ” Complementary Therapies in Medicine 52 (2020):102452.

[40] M. A. Nogueira,C. P. Oliveira,V. A. Ferreira Alves,J. T. Stefano,L. S. Rodrigues,R. S. Torrinhas, et al.,“Omega-3 Polyunsaturated Fatty Acids in Treating Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial, ” Clinical Nutrition 35, no. 3 (2016):578–586.

[41] S. Dasarathy,J. Dasarathy,A. Khiyami, et al.,“Double-blind Randomized Placebo-Controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis, ” Journal of Clinical Gastroenterology 49, no. 2 (2015):137–144.

[42] C. K. Argo,J. T. Patrie,C. Lackner, et al.,“Effects of n-3 Fish Oil on Metabolic and Histological Parameters in NASH: A Double-Blind, Randomized, Placebo-Controlled Trial, ” Journal of Hepatology 62, no. 1 (2015):190–197.

[43] R. Loomba,C. B. Sirlin,B. Ang, et al.,“Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART trial), ” Hepatology 61, no. 4 (2015):1239–1250.

[44] B. A Neuschwander-Tetri,R. Loomba,A. J. Sanyal, et al.,“Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial, ” Lancet 385, no. 9972 (2015):956–965.

[45] A. J. Sanyal,M. F. Abdelmalek,A. Suzuki,O. W. Cummings, and M. Chojkier,“No Significant Effects of Ethyl-eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial, ” Gastroenterology 147, no. 2 (2014):377–384.

[46] C. O. Zein,L. M. Yerian,P. Gogate, et al.,“Pentoxifylline Improves Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial, ” Hepatology 54, no. 5 (2011):1610–1619.

[47] Z. Younossi,Q. M. Anstee,M. Marietti, et al.,“Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention, ” Nature Reviews Gastroenterology & hepatology 15, no. 1 (2018):11–20.

[48] A. C. Sheka,O. Adeyi,J. Thompson,B. Hameed,P. A. Crawford, and S. Ikramuddin,“Nonalcoholic Steatohepatitis: A Review, ” Jama 323, no. 12 (2020):1175–1183.

[49] A. J. Sanyal,M. L. Van Natta,J. Clark, et al.,“Prospective Study of Outcomes in Adults With Nonalcoholic Fatty Liver Disease, ” New England Journal of Medicine 385, no. 17 (2021):1559–1569.

[50] D. Q. Huang,A. G. Singal,Y. Kono,D. J. H. Tan,H. B El-Serag, and R. Loomba,“Changing Global Epidemiology of Liver Cancer From 2010 to 2019: NASH Is the Fastest Growing Cause of Liver Cancer, ” Cell Metabolism 34, no. 7 (2022):969–977.

[51] L. F. Xue,W. H. Luo,X. X. He,F. M. Zhang, and Y. Chen,“Research Progress on Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Fatty Liver Disease, ” Infectious Diseases and Infection 32, no. 04 (2019):299–303.

[52] X. F. Tong and Y. M. Sun,“You H. Evaluation of Clinical Endpoint of New Drug Development for Nonalcoholic Steatohepatitis, ” Journal of Clinical Hepatology 37, no. 06 (2021):1249–1253.

[53] M. E. Rinella,F. Tacke,A. J. Sanyal, and Q. M. Anstee,“Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD, ” Journal of Hepatology 71, no. 4 (2019):823–833.

[54] I. Genua and K. Cusi,“Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies, ” Diabetes Spectrum 37, no. 1 (2024):48–58.

[55] I. Blazina and S. Selph,“Diabetes Drugs for Nonalcoholic Fatty Liver Disease: A Systematic Review, ” Systematic Reviews 8, no. 1 (2019):295.

[56] Z. Wang,H. Du,Y. Zhao, et al.,“Response to Pioglitazone in Non-Alcoholic Fatty Liver Disease Patients With vs. Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials, ” Frontiers in Endocrinology (Lausanne) 14 (2023):1111430.

[57] G. Jiang,C. Sun,X. Wang, et al.,“Hepatoprotective Mechanism of Silybum Marianum on Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification, ” Bioengineered 13, no. 3 (2022):5216–5235.

[58] M. L. Ding,A. Li, and H. W. Zhu,“Advances in the Treatment of Nonalcoholic Fatty Liver Disease, ” Infectious Diseases and Infection 36, no. 04 (2023):374–377.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.